Expression of HMP/AN2, a melanoma associated antigen, in murine cerebral gliomas: Potential for radioimmunotargeting

Journal of Neuro-Oncology

Volumn 94, Issue 1, 2009, Pages 21-30

  Paul, Asit K ^a,b   Ciesielski, Michael J ^a,c   Sajjad, Munawwar ^a   Wang, Xinhui ^c   Ferrone, Soldano ^a,c   Abdel Nabi, Hani ^a   Fenstermaker, Robert A ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROCHESTER GENERAL HOSPITAL   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Glioma; Human melanoma proteoglycan (HMP); microPET; Monoclonal antibodies; Radioimmunotargeting

Indexed keywords

HUMAN MELANOMA PROTEOGLYCAN; IODINE 124; MELANOMA ANTIGEN; MONOCLONAL ANTIBODY; PROTEIN AN2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CONTROLLED STUDY; CULTURE MEDIUM; FLOW CYTOMETRY; GLIOMA; GLIOMA CELL; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIOIMMUNOTHERAPY; TUMOR LOCALIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; IODINE RADIOISOTOPES; MALE; MICE; MICE, INBRED C57BL; MITOCHONDRIAL PROTEINS; MUSCLE PROTEINS; NEOPLASM TRANSPLANTATION; POSITRON-EMISSION TOMOGRAPHY; PROTEOGLYCANS; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 67650499798     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-9798-3     Document Type: Article

References (42)

1. Stupp R, Hegi ME, Gilbert MR, Chakravarti A (2007) Chemoradiotherapy in malignant glioma: Standard of care and future directions. J Clin Oncol 25:4127-4136. doi: 10.1200/JCO.2007.11.8554
2. Fenstermaker RA, Ciesielski MJ (2004) Immunotherapeutic strategies for malignant glioma. Cancer Control 11:181-191
3. Kurpad SN, Zhao XG, Wikstrand CJ, Batra SK, McLendon RE, Bigner DD (1995) Tumor antigens in astrocytic gliomas. Glia 15:244-256. doi: 10.1002/glia.440150306
4. Chai DD, Merchant RE, Rand R et al (1997) Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol 150:2143-2152
5. Sasaki M, Nakahira K, Kawano Y et al (2001) MAGE-E1, a new member of the melanoma-associated antigen gene family and its expression in human glioma. Cancer Res 61:4809-4814
6. Prins RM, Odesa SK, Liau LM (2003) Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res 63:8487-8491
7. Colapinto EV, Zalutsky MR, Archer GE et al (1990) Radioimmunotherapy of intracerebral human glioma xenografts with 131 I-labeled F(ab')2 fragments of monoclonal antibody Mel-14. Cancer Res 50:1822-1827
8. Schrappe M, Bumol TF, Apelgren LD et al (1992) Long-term growth suppression of human glioma xenografts by chemoimmunoconjugates of 4-desacetylvinblastine-3-carboxyhydrazide and monoclonal antibody 9.2.27. Cancer Res 52:3838-3844
9. Hjortland GO, Garman-Vik SS, Juell S et al (2004) Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme. J Neurosurg 100:320-327
10. Campoli MR, Chang CC, Kageshita T, Wang X, McCarthy JB, Ferrone S (2004) Human high molecular weight-melanoma-associated antigen (HMP): A melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol 24:267-296. doi: 10.1615/CritRevImmunol.v24.i4.40
11. Schrappe M, Klier FG, Spiro RC, Waltz TA, Reisfeld RA, Gladson CL (1991) Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. Cancer Res 51:4986-4993
12. Shoshan Y, Nishiyama A, Chang A et al (1999) Expression of oligodendrocyte progenitor cell antigens by gliomas: Implications for the histogenesis of brain tumors. Proc Natl Acad Sci USA 96:10361-10366. doi: 10.1073/pnas.96.18.10361
13. Chekenya M, Rooprai HK, Davies D, Levine JM, Butt AM, Pilkington GJ (1999) The NG2 chondroitin sulfate proteoglycan: Role in malignant progression of human brain tumours. Int J Dev Neurosci 17:421-435. doi: 10.1016/S0736-5748(99)00019-2
14. Chekenya M, Enger PO, Thorsen F et al (2002) The glial precursor proteoglycan, NG2, is expressed on tumour neovasculature by vascular pericytes in human malignant brain tumours. Neuropathol Appl Neurobiol 28:367-380. doi: 10.1046/j.1365-2990.2002.00412.x
15. Pluschke G, Vanek M, Evans A et al (1996) Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. Proc Natl Acad Sci USA 93:9710-9715. doi: 10.1073/pnas.93.18.9710
16. Nishiyama A, Dahlin KJ, Prince JT, Johnstone SR, Stallcup WB (1991) The primary structure of NG2, a novel membrane-spanning proteoglycan. J Cell Biol 114:359-371. doi: 10.1083/jcb.114.2.359
17. Stegmuller J, Schneider S, Hellwig A, Garwood J, Trotter J (2002) AN2, the murine homologue of NG2, is a surface antigen on glial precursor cells implicated in control of cell migration. J Neurocytol 31:497-505. doi: 10.1023/A:1025743731306
18. Chekenya M, Hjelstuen M, Enger PO et al (2002) NG2 proteoglycan promotes angiogenesis-dependent tumor growth in CNS by sequestering angiostatin. FASEB J 16:586-588
19. Chekenya M, Immervoll H (2007) NG2/HMP proteoglycan as a cancer therapeutic target. Methods Mol Biol 361:93-117
20. Temponi M, Gold AM, Ferrone S (1992) Binding parameters and idiotypic profile of the whole immunoglobulin and Fab' fragments of murine monoclonal antibody to distinct determinants of the human high molecular weight-melanoma associated antigen. Cancer Res 52:2497-2503
21. Kusama M, Kageshita T, Chen ZJ, Ferrone S (1989) Characterization of syngeneic antiidiotypic monoclonal antibodies to murine antihuman high molecular weight-melanoma associated antigen monoclonal antibodies. J Immunol 143:3844-3852
22. Ghose T, Ferrone S, Blair AH et al (1991) Regression of human melanoma xenografts in nude mice injected with methotrexate linked to monoclonal antibody 225.28 to human high molecular weight-melanoma associated antigen. Cancer Immunol Immunother 34:90-96. doi: 10.1007/BF01741341
23. Siccardi AG, Buraggi GL, Callegaro L et al (1986) Multicenter study of immunoscintigraphy with radiolabeled monoclonal antibodies in patients with melanoma. Cancer Res 46:4817-4822
24. Szatmari T, Lumniczky K, Desaknai S et al (2006) Detailed characterization of the murine glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci 97:546-553. doi: 10.1111/ j.1349-7006.2006.00208.x
25. Candolfi M, Curtin JF, Nichols WS et al (2007) Intracranial glioblastoma models in preclinical neuro-oncology: Neuropathological characterization and tumor progression. J Neurooncol 85:133-148. doi: 10.1007/ s11060-007-9400-9
26. Cha S, Johnson G, Wadghiri YZ et al (2003) Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: Correlation with histopathology. Magn Reson Med 49:848-855. doi: 10.1002/mrm.10446
27. Temponi M, Kageshita T, Perosa F, Ono R, Okada H, Ferrone S (1989) Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: Comparison with other methods of purification. Hybridoma 8:85-95
28. Sajjad M, Bars E, Nabi HA (2006) Optimization of 124 I production via 124 Te(p, n) 124 I reaction. Appl Radiat Isot 64:965-970. doi: 10.1016/ j.apradiso.2006.04.004
29. Vaidyanathan G, Zalutsky MR (1990) Radioiodination of antibodies via N -succinimidyl 2,4-dimethoxy-3-(trialkylstannyl)benzoates. Bioconjug Chem 1:387-393. doi: 10.1021/bc00006a004 2,4-dimethoxy-3-(trialkylstannyl)benzoates. Bioconjug Chem 1:387-393. doi: 10.1021/bc00006a004
30. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr (1984) Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72:77-89. doi: 10.1016/0022-1759(84)90435-6
31. Kim JS, Lee JS, Im KC et al (2007) Performance measurement of the microPET focus 120 scanner. J Nucl Med 48:1527-1535. doi: 10.2967/ jnumed.107.040550
32. Moshakis V, McIlhinney R, Raghavan D, Neville AM (1981) Monoclonal antibodies to detect human tumours: An experimental approach. J Clin Pathol 34:314-319. doi: 10.1136/jcp.34.3.314
33. Jones TR, Ruoslahti E, Schold SC, Bigner DD (1982) Fibronectin and glial fibrillary acidic protein expression in normal human brain and anaplastic human gliomas. Cancer Res 42:168-177
34. Dawson MR, Polito A, Levine JM, Reynolds R (2003) NG2-expressing glial progenitor cells: An abundant and widespread population of cycling cells in the adult rat CNS. Mol Cell Neurosci 24:476-488. doi: 10.1016/ S1044-7431(03)00210-0
35. Stallcup WB, Beasley L (1987) Bipotential glial precursor cells of the optic nerve express the NG2 proteoglycan. J Neurosci 7:2737-2744
36. Reardon DA, Akabani G, Coleman RE et al (2006) Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: Phase II study results. J Clin Oncol 24:115-122. doi: 10.1200/JCO.2005.03.4082
37. Quang TS, Brady LW (2004) Radioimmunotherapy as a novel treatment regimen: 125 I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int J Radiat Oncol Biol Phys 58:972-975. doi: 10.1016/j.ijrobp.2003.09.096
38. Riva P, Arista A, Sturiale C et al (1992) Treatment of intracranial human glioblastoma by direct intratumoral administration of 131 I-labelled anti-tenascin monoclonal antibody BC-2. Int J Cancer 51:7-13. doi: 10.1002/ijc.2910510103
39. Yuan H, Gaber MW, Boyd K, Wilson CM, Kiani MF, Merchant TE (2006) Effects of fractionated radiation on the brain vasculature in a murine model: Blood-brain barrier permeability, astrocyte proliferation, and ultrastructural changes. Int J Radiat Oncol Biol Phys 66:860-866. doi: 10.1016/j.ijrobp.2006.06.043
40. Petronzelli F, Pelliccia A, Anastasi AM et al (2005) Improved tumor targeting by combined use of two antitenascin antibodies. Clin Cancer Res 11:7137s-7145s. doi: 10.1158/1078-0432.CCR-1004-0007
41. Grana C, Chinol M, Robertson C et al (2002) Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br J Cancer 86:207-212. doi: 10.1038/sj.bjc.6600047
42. Sundaresan G, Yazaki PJ, Shively JE et al (2003) 124 I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 44:1962-1969